{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T03:46:20Z","timestamp":1790739980409,"version":"4.1.0"},"reference-count":77,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1007\/s40262-022-01135-0","type":"journal-article","created":{"date-parts":[[2022,7,4]],"date-time":"2022-07-04T01:02:51Z","timestamp":1656896571000},"page":"955-972","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Clinical Pharmacokinetics and Pharmacodynamics of Fostamatinib and Its Active Moiety R406"],"prefix":"10.1007","volume":"61","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5444-2443","authenticated-orcid":false,"given":"Ryosuke","family":"Matsukane","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimitaka","family":"Suetsugu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4846-3421","authenticated-orcid":false,"given":"Takeshi","family":"Hirota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3543-2562","authenticated-orcid":false,"given":"Ichiro","family":"Ieiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,7,4]]},"reference":[{"key":"1135_CR1","doi-asserted-by":"publisher","first-page":"9","DOI":"10.2217\/imt-2017-0097","volume":"10","author":"A Newland","year":"2018","unstructured":"Newland A, Lee E-J, McDonald V, Bussel JB. Fostamatinib for persistent\/chronic adult immune thrombocytopenia. Immunotherapy. 2018;10:9\u201325.","journal-title":"Immunotherapy"},{"key":"1135_CR2","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1111\/bjh.16958","volume":"190","author":"R Kapur","year":"2020","unstructured":"Kapur R. Fine-tuning the treatment toolbox of immune thrombocytopenia: fostamatinib as a second-line therapy. Br J Haematol. 2020;190:817\u20138.","journal-title":"Br J Haematol"},{"key":"1135_CR3","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1016\/S0006-291X(88)80401-7","volume":"152","author":"K Sakai","year":"1988","unstructured":"Sakai K, Nakamura S, Sada K, Kobayashi T, Uno H, Yamamura H. Characterization of partially purified cytosolic protein-tyrosine kinase from porcine spleen. Biochem Biophys Res Commun. 1988;152:1123\u201330.","journal-title":"Biochem Biophys Res Commun"},{"key":"1135_CR4","doi-asserted-by":"publisher","first-page":"15790","DOI":"10.1016\/S0021-9258(18)98478-4","volume":"266","author":"T Taniguchi","year":"1991","unstructured":"Taniguchi T, Kobayashi T, Kondo J, Takahashi K, Nakamura H, Suzuki J, et al. Molecular cloning of a porcine gene syk that encodes a 72-kDa protein-tyrosine kinase showing high susceptibility to proteolysis. J Biol Chem. 1991;266:15790\u20136.","journal-title":"J Biol Chem"},{"key":"1135_CR5","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1007\/BF00189976","volume":"40","author":"G Ku","year":"1994","unstructured":"Ku G, Malissen B, Mattei MG. Chromosomal location of the Syk and ZAP-70 tyrosine kinase genes in mice and humans. Immunogenetics. 1994;40:300\u20132.","journal-title":"Immunogenetics"},{"key":"1135_CR6","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1038\/nri2765","volume":"10","author":"A M\u00f3csai","year":"2010","unstructured":"M\u00f3csai A, Ruland J, Tybulewicz VLJ. The SYK tyrosine kinase: a crucial player in diverse biological functions. Nat Rev Immunol. 2010;10:387\u2013402.","journal-title":"Nat Rev Immunol"},{"key":"1135_CR7","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1016\/j.tips.2014.05.007","volume":"35","author":"RL Geahlen","year":"2014","unstructured":"Geahlen RL. Getting Syk: spleen tyrosine kinase as a therapeutic target. Trends Pharmacol Sci. 2014;35:414\u201322.","journal-title":"Trends Pharmacol Sci"},{"key":"1135_CR8","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1002\/ajh.25125","volume":"93","author":"J Bussel","year":"2018","unstructured":"Bussel J, Arnold DM, Grossbard E, Mayer J, Treli\u0144ski J, Homenda W, et al. Fostamatinib for the treatment of adult persistent and chronic immune thrombocytopenia: results of two phase 3, randomized, placebo-controlled trials. Am J Hematol. 2018;93:921\u201330.","journal-title":"Am J Hematol"},{"key":"1135_CR9","doi-asserted-by":"publisher","first-page":"3829","DOI":"10.1182\/bloodadvances.2019000966","volume":"3","author":"C Neunert","year":"2019","unstructured":"Neunert C, Terrell DR, Arnold DM, Buchanan G, Cines DB, Cooper N, et al. American Society of Hematology 2019 guidelines for immune thrombocytopenia. Blood Adv. 2019;3:3829\u201366.","journal-title":"Blood Adv"},{"key":"1135_CR10","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1002\/ajh.21833","volume":"85","author":"DR Terrell","year":"2010","unstructured":"Terrell DR, Beebe LA, Vesely SK, Neas BR, Segal JB, George JN. The incidence of immune thrombocytopenic purpura in children and adults: a critical review of published reports. Am J Hematol. 2010;85:174\u201380.","journal-title":"Am J Hematol"},{"key":"1135_CR11","doi-asserted-by":"publisher","first-page":"4934","DOI":"10.1182\/blood.V128.22.4934.4934","volume":"128","author":"JY Lee","year":"2016","unstructured":"Lee JY, Lee JH, Lee J-O, Bang S-M. Epidemiology and management of immune thrombocytopenia: a nationwide population-based study in Korea. Blood. 2016;128:4934.","journal-title":"Blood"},{"key":"1135_CR12","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1007\/s40267-018-0551-x","volume":"34","author":"K McKeage","year":"2018","unstructured":"McKeage K, Lyseng-Williamson KA. Fostamatinib in chronic immune thrombocytopenia: a profile of its use in the USA. Drugs Ther Perspect. 2018;34:451\u20136.","journal-title":"Drugs Ther Perspect."},{"key":"1135_CR13","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1002\/ajh.25444","volume":"94","author":"JB Bussel","year":"2019","unstructured":"Bussel JB, Arnold DM, Boxer MA, Cooper N, Mayer J, Zayed H, et al. Long-term fostamatinib treatment of adults with immune thrombocytopenia during the phase 3 clinical trial program. Am J Hematol. 2019;94:546\u201353.","journal-title":"Am J Hematol"},{"key":"1135_CR14","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1016\/j.clim.2007.03.543","volume":"124","author":"PR Pine","year":"2007","unstructured":"Pine PR, Chang B, Schoettler N, Banquerigo ML, Wang S, Lau A, et al. Inflammation and bone erosion are suppressed in models of rheumatoid arthritis following treatment with a novel Syk inhibitor. Clin Immunol. 2007;124:244\u201357.","journal-title":"Clin Immunol"},{"key":"1135_CR15","doi-asserted-by":"publisher","first-page":"3309","DOI":"10.1002\/art.23992","volume":"58","author":"ME Weinblatt","year":"2008","unstructured":"Weinblatt ME, Kavanaugh A, Burgos-Vargas R, Dikranian AH, Medrano-Ramirez G, Morales-Torres JL, et al. Treatment of rheumatoid arthritis with a Syk kinase inhibitor: a twelve-week, randomized, placebo-controlled trial. Arthritis Rheum. 2008;58:3309\u201318.","journal-title":"Arthritis Rheum"},{"key":"1135_CR16","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1056\/NEJMoa1000500","volume":"363","author":"ME Weinblatt","year":"2010","unstructured":"Weinblatt ME, Kavanaugh A, Genovese MC, Musser TK, Grossbard EB, Magilavy DB. An oral spleen tyrosine kinase (Syk) inhibitor for rheumatoid arthritis. N Engl J Med. 2010;363:1303\u201312.","journal-title":"N Engl J Med"},{"key":"1135_CR17","doi-asserted-by":"publisher","first-page":"369","DOI":"10.3899\/jrheum.120923","volume":"40","author":"ME Weinblatt","year":"2013","unstructured":"Weinblatt ME, Kavanaugh A, Genovese MC, Jones DA, Musser TK, Grossbard EB, et al. Effects of fostamatinib (R788), an oral spleen tyrosine kinase inhibitor, on health-related quality of life in patients with active rheumatoid arthritis: analyses of patient-reported outcomes from a randomized, double-blind, placebo-controlled trial. J Rheumatol. 2013;40:369\u201378.","journal-title":"J Rheumatol"},{"key":"1135_CR18","doi-asserted-by":"publisher","first-page":"3255","DOI":"10.1002\/art.38851","volume":"66","author":"ME Weinblatt","year":"2014","unstructured":"Weinblatt ME, Genovese MC, Ho M, Hollis S, Rosiak-Jedrychowicz K, Kavanaugh A, et al. Effects of fostamatinib, an oral spleen tyrosine kinase inhibitor, in rheumatoid arthritis patients with an inadequate response to methotrexate: results from a phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis Rheumatol. 2014;66:3255\u201364.","journal-title":"Arthritis Rheumatol"},{"key":"1135_CR19","first-page":"S198","volume":"65","author":"P Dawes","year":"2013","unstructured":"Dawes P, Dimic A, Genovese MC, van der Heijde D, Jenkins M, O\u2019Brien C, et al. OSKIRA-2: a phase III, multicenter, randomized, double-blind, placebo-controlled parallel-group study of 2 dosing regimens of fostamatinib in rheumatoid arthritis patients with an inadequate response to disease-modifying antirheumatic drugs. Arthritis Rheum. 2013;65:S198\u20139.","journal-title":"Arthritis Rheum"},{"key":"1135_CR20","doi-asserted-by":"publisher","first-page":"2120","DOI":"10.3899\/jrheum.140238","volume":"41","author":"MC Genovese","year":"2014","unstructured":"Genovese MC, van der Heijde DM, Keystone EC, Spindler AJ, Benhamou C, Kavanaugh A, et al. A phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study of 2 dosing regimens of fostamatinib in patients with rheumatoid arthritis with an inadequate response to a tumor necrosis factor-\u03b1 antagonist. J Rheumatol. 2014;41:2120\u20138.","journal-title":"J Rheumatol"},{"key":"1135_CR21","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1136\/annrheumdis-2014-205361","volume":"74","author":"PC Taylor","year":"2015","unstructured":"Taylor PC, Genovese MC, Greenwood M, Ho M, Nasonov E, Oemar B, et al. OSKIRA-4: a phase IIb randomised, placebo-controlled study of the efficacy and safety of fostamatinib monotherapy. Ann Rheum Dis. 2015;74:2123\u20139.","journal-title":"Ann Rheum Dis"},{"key":"1135_CR22","doi-asserted-by":"publisher","first-page":"3154","DOI":"10.1182\/blood-2008-07-166439","volume":"113","author":"A Podolanczuk","year":"2009","unstructured":"Podolanczuk A, Lazarus AH, Crow AR, Grossbard E, Bussel JB. Of mice and men: an open-label pilot study for treatment of immune thrombocytopenic purpura by an inhibitor of Syk. Blood. 2009;113:3154\u201360.","journal-title":"Blood"},{"key":"1135_CR23","doi-asserted-by":"publisher","first-page":"2884","DOI":"10.1093\/rheumatology\/keaa732","volume":"60","author":"Y Tanaka","year":"2021","unstructured":"Tanaka Y, Millson D, Iwata S, Nakayamada S. Safety and efficacy of fostamatinib in rheumatoid arthritis patients with an inadequate response to methotrexate in phase II OSKIRA-ASIA-1 and OSKIRA-ASIA-1X study. Rheumatology. 2021;60:2884\u201395.","journal-title":"Rheumatology"},{"key":"1135_CR24","doi-asserted-by":"publisher","first-page":"3518","DOI":"10.1182\/blood-2019-126509","volume":"134","author":"KA Rogers","year":"2019","unstructured":"Rogers KA, Boxer MA, Choi MY, Agajanian R, Arnold DM, Broome CM, et al. Fostamatinib, a spleen tyrosine kinase (SYK) inhibitor, for the treatment of warm antibody autoimmune hemolytic anemia (wAIHA): final results of the phase 2, multicenter, open-label study. Blood. 2019;134:3518.","journal-title":"Blood"},{"key":"1135_CR25","doi-asserted-by":"publisher","first-page":"3859","DOI":"10.3390\/jcm9123859","volume":"9","author":"W Barcellini","year":"2020","unstructured":"Barcellini W, Zaninoni A, Giannotta JA, Fattizzo B. New insights in autoimmune hemolytic anemia: from pathogenesis to therapy stage 1. J Clin Med. 2020;9:3859.","journal-title":"J Clin Med"},{"key":"1135_CR26","doi-asserted-by":"publisher","first-page":"2578","DOI":"10.1182\/blood-2009-08-236471","volume":"115","author":"JW Friedberg","year":"2010","unstructured":"Friedberg JW, Sharman J, Sweetenham J, Johnston PB, Vose JM, Lacasce A, et al. Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia. Blood. 2010;115:2578\u201385.","journal-title":"Blood"},{"key":"1135_CR27","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.ejca.2015.10.005","volume":"54","author":"IW Flinn","year":"2016","unstructured":"Flinn IW, Bartlett NL, Blum KA, Ardeshna KM, LaCasce AS, Flowers CR, et al. A phase II trial to evaluate the efficacy of fostamatinib in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). Eur J Cancer. 2016;54:11\u20137.","journal-title":"Eur J Cancer"},{"key":"1135_CR28","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1159\/000446879","volume":"133","author":"TK-W Ma","year":"2016","unstructured":"Ma TK-W, McAdoo SP, Tam FW-K. Spleen tyrosine kinase: a crucial player and potential therapeutic target in renal disease. Nephron. 2016;133:261\u20139.","journal-title":"Nephron"},{"key":"1135_CR29","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1016\/j.semnephrol.2018.05.019","volume":"38","author":"S McAdoo","year":"2018","unstructured":"McAdoo S, Tam FWK. Role of the spleen tyrosine kinase pathway in driving inflammation in IgA nephropathy. Semin Nephrol. 2018;38:496\u2013503.","journal-title":"Semin Nephrol"},{"key":"1135_CR30","doi-asserted-by":"publisher","first-page":"S168","DOI":"10.1016\/j.ekir.2019.05.431","volume":"4","author":"WKF Tam","year":"2019","unstructured":"Tam WKF, Tumlin J, Barratt J, Rovin HB, Roberts SDI, Roufosse C, et al. SUN-036 Spleen tyrosine kinase (SYK) inhibition in IgA nephropathy: a global, phase II, randomized placebo-controlled trial of fostamatinib. Kidney Int Rep. 2019;4:S168.","journal-title":"Kidney Int Rep."},{"key":"1135_CR31","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1016\/j.kint.2019.12.014","volume":"97","author":"SP McAdoo","year":"2020","unstructured":"McAdoo SP, Prendecki M, Tanna A, Bhatt T, Bhangal G, McDaid J, et al. Spleen tyrosine kinase inhibition is an effective treatment for established vasculitis in a pre-clinical model. Kidney Int. 2020;97:1196\u2013207.","journal-title":"Kidney Int"},{"key":"1135_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2020.100145","volume":"1","author":"N Tabassum","year":"2020","unstructured":"Tabassum N, Zhang H, Stebbing J. Repurposing fostamatinib to combat SARS-CoV-2-induced acute lung injury. Cell Rep Med. 2020;1: 100145.","journal-title":"Cell Rep Med."},{"key":"1135_CR33","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1093\/infdis\/jiaa789","volume":"223","author":"JR Strich","year":"2021","unstructured":"Strich JR, Ramos-Benitez MJ, Randazzo D, Stein SR, Babyak A, Davey RT, et al. Fostamatinib inhibits neutrophils extracellular traps induced by COVID-19 patient plasma: a potential therapeutic. J Infect Dis. 2021;223:981\u20134.","journal-title":"J Infect Dis"},{"key":"1135_CR34","doi-asserted-by":"crossref","unstructured":"Strich JR, Tian X, Samour M, King CS, Shlobin O, Reger R, et al. Fostamatinib for the treatment of hospitalized adults with Coronavirus Disease 2019: a randomized trial. Clin Infect Dis. 2021; p. ciab732.","DOI":"10.1093\/cid\/ciab732"},{"key":"1135_CR35","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1124\/jpet.106.109058","volume":"319","author":"S Braselmann","year":"2006","unstructured":"Braselmann S, Taylor V, Zhao H, Wang S, Sylvain C, Baluom M, et al. R406, an orally available spleen tyrosine kinase inhibitor blocks fc receptor signaling and reduces immune complex-mediated inflammation. J Pharmacol Exp Ther. 2006;319:998\u20131008.","journal-title":"J Pharmacol Exp Ther"},{"key":"1135_CR36","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1038\/s41588-021-00837-8","volume":"53","author":"I Aksentijevich","year":"2021","unstructured":"Aksentijevich I. The sickening consequences of too much SYK signaling. Nat Genet. 2021;53:432\u20134.","journal-title":"Nat Genet"},{"key":"1135_CR37","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1111\/j.1747-0285.2009.00785.x","volume":"73","author":"AG Villase\u00f1or","year":"2009","unstructured":"Villase\u00f1or AG, Kondru R, Ho H, Wang S, Papp E, Shaw D, et al. Structural insights for design of potent spleen tyrosine kinase inhibitors from crystallographic analysis of three inhibitor complexes. Chem Biol Drug Des. 2009;73:466\u201370.","journal-title":"Chem Biol Drug Des"},{"key":"1135_CR38","unstructured":"US Food and Drug Administration. Tavalisse (fostamatinib disodium hexahydrate) [multi-disciplinary review]. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2018\/209299Orig1s000MultidisciplineR.pdf. Accessed 22 Mar 2022."},{"key":"1135_CR39","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1083\/jcb.200112113","volume":"157","author":"A Obergfell","year":"2002","unstructured":"Obergfell A, Eto K, Mocsai A, Buensuceso C, Moores SL, Brugge JS, et al. Coordinate interactions of Csk, Src, and Syk kinases with [alpha]IIb[beta]3 initiate integrin signaling to the cytoskeleton. J Cell Biol. 2002;157:265\u201375.","journal-title":"J Cell Biol"},{"key":"1135_CR40","doi-asserted-by":"publisher","DOI":"10.1002\/prp2.175","volume":"3","author":"MG Rolf","year":"2015","unstructured":"Rolf MG, Curwen JO, Veldman-Jones M, Eberlein C, Wang J, Harmer A, et al. In vitro pharmacological profiling of R406 identifies molecular targets underlying the clinical effects of fostamatinib. Pharmacol Res Perspect. 2015;3: e00175.","journal-title":"Pharmacol Res Perspect"},{"key":"1135_CR41","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1038\/bjp.2008.361","volume":"155","author":"CN Wilson","year":"2008","unstructured":"Wilson CN. Adenosine receptors and asthma in humans. Br J Pharmacol. 2008;155:475\u201386.","journal-title":"Br J Pharmacol"},{"issue":"Suppl. 1","key":"1135_CR42","doi-asserted-by":"publisher","first-page":"S446","DOI":"10.1038\/bjp.2008.22","volume":"153","author":"RA Brown","year":"2008","unstructured":"Brown RA, Spina D, Page CP. Adenosine receptors and asthma. Br J Pharmacol. 2008;153(Suppl. 1):S446\u201356.","journal-title":"Br J Pharmacol"},{"key":"1135_CR43","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1165\/rcmb.2005-0298OC","volume":"34","author":"S Matsubara","year":"2006","unstructured":"Matsubara S, Koya T, Takeda K, Joetham A, Miyahara N, Pine P, et al. Syk activation in dendritic cells is essential for airway hyperresponsiveness and inflammation. Am J Respir Cell Mol Biol. 2006;34:426\u201333.","journal-title":"Am J Respir Cell Mol Biol"},{"key":"1135_CR44","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1164\/rccm.200503-361OC","volume":"173","author":"S Matsubara","year":"2006","unstructured":"Matsubara S, Li G, Takeda K, Loader JE, Pine P, Masuda ES, et al. Inhibition of spleen tyrosine kinase prevents mast cell activation and airway hyperresponsiveness. Am J Respir Crit Care Med. 2006;173:56\u201363.","journal-title":"Am J Respir Crit Care Med"},{"key":"1135_CR45","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1093\/cvr\/cvz022","volume":"115","author":"J Versmissen","year":"2019","unstructured":"Versmissen J, Mirabito Colafella KM, Koolen SLW, Danser AHJ. Vascular cardio-oncology: vascular endothelial growth factor inhibitors and hypertension. Cardiovasc Res. 2019;115:904\u201314.","journal-title":"Cardiovasc Res"},{"key":"1135_CR46","doi-asserted-by":"publisher","first-page":"2308","DOI":"10.1111\/bph.12559","volume":"171","author":"M Skinner","year":"2014","unstructured":"Skinner M, Philp K, Lengel D, Coverley L, Lamm Bergstr\u00f6m E, Glaves P, et al. The contribution of VEGF signalling to fostamatinib-induced blood pressure elevation. Br J Pharmacol. 2014;171:2308\u201320.","journal-title":"Br J Pharmacol"},{"key":"1135_CR47","doi-asserted-by":"publisher","DOI":"10.1002\/prp2.176","volume":"3","author":"D Lengel","year":"2015","unstructured":"Lengel D, Lamm Bergstr\u00f6m E, Barthlow H, Oldman K, Musgrove H, Harmer A, et al. Prevention of fostamatinib-induced blood pressure elevation by antihypertensive agents. Pharmacol Res Perspect. 2015;3: e00176.","journal-title":"Pharmacol Res Perspect"},{"key":"1135_CR48","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.1124\/dmd.110.032151","volume":"38","author":"DJ Sweeny","year":"2010","unstructured":"Sweeny DJ, Li W, Clough J, Bhamidipati S, Singh R, Park G, et al. Metabolism of fostamatinib, the oral methylene phosphate prodrug of the spleen tyrosine kinase inhibitor R406 in humans: contribution of hepatic and gut bacterial processes to the overall biotransformation. Drug Metab Dispos. 2010;38:1166\u201376.","journal-title":"Drug Metab Dispos"},{"key":"1135_CR49","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1007\/s00228-016-2156-4","volume":"73","author":"T Flanagan","year":"2017","unstructured":"Flanagan T, Martin P, Gillen M, Mathews D, Lisbon E, Kruusm\u00e4gi M. Effects of ranitidine (antacid), food, and formulation on the pharmacokinetics of fostamatinib: results from five phase I clinical studies. Eur J Clin Pharmacol. 2017;73:185\u201395.","journal-title":"Eur J Clin Pharmacol"},{"key":"1135_CR50","unstructured":"US Food and Drug Administration. Tavalisse (fostamatinib disodium hexahydrate) [package insert]. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/209299lbl.pdf. Accessed 22 Mar 2022."},{"key":"1135_CR51","unstructured":"European Medicines Agency. Tavlesse (fostamatinib disodium hexahydrate) [product information]. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/tavlesse-epar-product-information_en.pdf. Accessed 22 Mar 2022."},{"key":"1135_CR52","doi-asserted-by":"publisher","first-page":"2811","DOI":"10.1016\/j.clinthera.2015.09.018","volume":"37","author":"P Martin","year":"2015","unstructured":"Martin P, Gillen M, Millson D, Oliver S, Brealey C, Elsby R, et al. Effects of fostamatinib on the pharmacokinetics of digoxin (a P-glycoprotein substrate): results from in vitro and phase I clinical studies. Clin Ther. 2015;37:2811\u201322.","journal-title":"Clin Ther"},{"key":"1135_CR53","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1111\/bcp.12048","volume":"76","author":"M Baluom","year":"2013","unstructured":"Baluom M, Grossbard EB, Mant T, Lau DTW. Pharmacokinetics of fostamatinib, a spleen tyrosine kinase (SYK) inhibitor, in healthy human subjects following single and multiple oral dosing in three phase I studies. Br J Clin Pharmacol. 2013;76:78\u201388.","journal-title":"Br J Clin Pharmacol"},{"key":"1135_CR54","unstructured":"European Medicines Agency. Tavlesse (fostamatinib disodium hexahydrate) [assessment report]. https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/tavlesse-epar-public-assessment-report_en.pdf. Accessed 22 Mar 2022."},{"key":"1135_CR55","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.2217\/imt-2020-0215","volume":"12","author":"A Newland","year":"2020","unstructured":"Newland A, McDonald V. Fostamatinib: a review of its clinical efficacy and safety in the management of chronic adult immune thrombocytopenia. Immunotherapy. 2020;12:1325\u201340.","journal-title":"Immunotherapy"},{"key":"1135_CR56","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.jmb.2005.07.075","volume":"353","author":"J Ghuman","year":"2005","unstructured":"Ghuman J, Zunszain PA, Petitpas I, Bhattacharya AA, Otagiri M, Curry S. Structural basis of the drug-binding specificity of human serum albumin. J Mol Biol. 2005;353:38\u201352.","journal-title":"J Mol Biol"},{"key":"1135_CR57","doi-asserted-by":"publisher","first-page":"2823","DOI":"10.1016\/j.clinthera.2015.09.016","volume":"37","author":"P Martin","year":"2015","unstructured":"Martin P, Oliver S, Gillen M, Marbury T, Millson D. Pharmacokinetic properties of fostamatinib in patients with renal or hepatic impairment: results from 2 phase I clinical studies. Clin Ther. 2015;37:2823\u201336.","journal-title":"Clin Ther"},{"key":"1135_CR58","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1007\/s40268-015-0118-4","volume":"16","author":"P Martin","year":"2016","unstructured":"Martin P, Gillen M, Millson D, Oliver S, Brealey C, Grossbard EB, et al. Effects of CYP3A4 inhibitors ketoconazole and verapamil and the CYP3A4 inducer rifampicin on the pharmacokinetic parameters of fostamatinib: results from in vitro and phase I clinical studies. Drugs R D. 2016;16:81\u201392.","journal-title":"Drugs R D."},{"key":"1135_CR59","doi-asserted-by":"publisher","first-page":"415","DOI":"10.3109\/00498251003734244","volume":"40","author":"DJ Sweeny","year":"2010","unstructured":"Sweeny DJ, Li W, Grossbard E, Lau DTW. Contribution of gut bacteria to the metabolism of the spleen tyrosine kinase (Syk) inhibitor R406 in cynomolgus monkey. Xenobiotica. 2010;40:415\u201323.","journal-title":"Xenobiotica"},{"key":"1135_CR60","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1177\/0091270010381496","volume":"51","author":"M Baluom","year":"2011","unstructured":"Baluom M, Samara E, Grossbard EB, Lau DT-W. Fostamatinib, a Syk-kinase inhibitor, does not affect methotrexate pharmacokinetics in patients with rheumatoid arthritis. J Clin Pharmacol. 2011;51:1310\u20138.","journal-title":"J Clin Pharmacol"},{"key":"1135_CR61","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1007\/s40268-015-0120-x","volume":"16","author":"P Martin","year":"2016","unstructured":"Martin P, Gillen M, Ritter J, Mathews D, Brealey C, Surry D, et al. Effects of fostamatinib on the pharmacokinetics of oral contraceptive, warfarin, and the statins rosuvastatin and simvastatin: results from phase I clinical studies. Drugs R D. 2016;16:93\u2013107.","journal-title":"Drugs R D."},{"key":"1135_CR62","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/S0163-7258(96)00140-4","volume":"73","author":"LS Kaminsky","year":"1997","unstructured":"Kaminsky LS, Zhang ZY. Human P450 metabolism of warfarin. Pharmacol Ther. 1997;73:67\u201374.","journal-title":"Pharmacol Ther"},{"key":"1135_CR63","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1111\/j.1365-2125.2011.04051.x","volume":"73","author":"S Lane","year":"2012","unstructured":"Lane S, Al-Zubiedi S, Hatch E, Matthews I, Jorgensen AL, Deloukas P, et al. The population pharmacokinetics of R- and S-warfarin: effect of genetic and clinical factors. Br J Clin Pharmacol. 2012;73:66\u201376.","journal-title":"Br J Clin Pharmacol"},{"key":"1135_CR64","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1002\/cpdd.243","volume":"5","author":"P Martin","year":"2016","unstructured":"Martin P, Gillen M, Millson D, Oliver S, Brealey C, Surry D, et al. Effects of fostamatinib on the pharmacokinetics of the CYP2C8 substrate pioglitazone: results from in vitro and phase 1 clinical studies. Clin Pharmacol Drug Dev. 2016;5:170\u20139.","journal-title":"Clin Pharmacol Drug Dev."},{"key":"1135_CR65","unstructured":"U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER). In vitro drug interaction studies: cytochrome P450 enzyme- and transporter-mediated drug interactions guidance for industry. https:\/\/www.fda.gov\/media\/134582\/download. Accessed 22 Mar 2022."},{"key":"1135_CR66","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1124\/dmd.115.066795","volume":"44","author":"R Elsby","year":"2016","unstructured":"Elsby R, Martin P, Surry D, Sharma P, Fenner K. Solitary inhibition of the breast cancer resistance protein efflux transporter results in a clinically significant drug-drug interaction with rosuvastatin by causing up to a 2-fold increase in statin exposure. Drug Metab Dispos. 2016;44:398\u2013408.","journal-title":"Drug Metab Dispos"},{"key":"1135_CR67","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1124\/dmd.106.011866","volume":"35","author":"CQ Xia","year":"2007","unstructured":"Xia CQ, Liu N, Miwa GT, Gan L-S. Interactions of cyclosporin a with breast cancer resistance protein. Drug Metab Dispos. 2007;35:576\u201382.","journal-title":"Drug Metab Dispos"},{"key":"1135_CR68","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejps.2020.105593","volume":"156","author":"Z S\u00e1f\u00e1r","year":"2021","unstructured":"S\u00e1f\u00e1r Z, Kecskem\u00e9ti G, Moln\u00e1r J, Kurunczi A, Szab\u00f3 Z, Jan\u00e1ky T, et al. Inhibition of ABCG2\/BCRP-mediated transport-correlation analysis of various expression systems and probe substrates. Eur J Pharm Sci. 2021;156: 105593.","journal-title":"Eur J Pharm Sci"},{"key":"1135_CR69","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1038\/clpt.2009.79","volume":"86","author":"JE Keskitalo","year":"2009","unstructured":"Keskitalo JE, Zolk O, Fromm MF, Kurkinen KJ, Neuvonen PJ, Niemi M. ABCG2 polymorphism markedly affects the pharmacokinetics of atorvastatin and rosuvastatin. Clin Pharmacol Ther. 2009;86:197\u2013203.","journal-title":"Clin Pharmacol Ther"},{"key":"1135_CR70","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1007\/s40265-013-0072-9","volume":"73","author":"VM Alla","year":"2013","unstructured":"Alla VM, Agrawal V, DeNazareth A, Mohiuddin S, Ravilla S, Rendell M. A reappraisal of the risks and benefits of treating to target with cholesterol lowering drugs. Drugs. 2013;73:1025\u201354.","journal-title":"Drugs"},{"key":"1135_CR71","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1002\/jcph.406","volume":"55","author":"J Maringwa","year":"2015","unstructured":"Maringwa J, K\u00e5gedal M, Hamr\u00e9n UW, Martin P, Cox E, Hamr\u00e9n B. Pharmacokinetic-pharmacodynamic modeling of fostamatinib efficacy on ACR20 to support dose selection in patients with rheumatoid arthritis (RA). J Clin Pharmacol. 2015;55:328\u201335.","journal-title":"J Clin Pharmacol"},{"key":"1135_CR72","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1002\/jcph.341","volume":"54","author":"E Bostr\u00f6m","year":"2014","unstructured":"Bostr\u00f6m E, \u00d6hrn F, Hanze E, Sandstr\u00f6m M, Martin P, W\u00e4hlby-Hamr\u00e9n U. Exposure vs. response of blood pressure in patients with rheumatoid arthritis following treatment with fostamatinib. J Clin Pharmacol. 2014;54:1337\u201346.","journal-title":"J Clin Pharmacol"},{"key":"1135_CR73","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2020.100137","volume":"1","author":"M Kost-Alimova","year":"2020","unstructured":"Kost-Alimova M, Sidhom E-H, Satyam A, Chamberlain BT, Dvela-Levitt M, Melanson M, et al. A high-content screen for mucin-1-reducing compounds identifies fostamatinib as a candidate for rapid repurposing for acute lung injury. Cell Rep Med. 2020;1: 100137.","journal-title":"Cell Rep Med."},{"key":"1135_CR74","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1159\/000233282","volume":"27","author":"L Shen","year":"2009","unstructured":"Shen L, Su L, Turner JR. Mechanisms and functional implications of intestinal barrier defects. Dig Dis. 2009;27:443\u20139.","journal-title":"Dig Dis"},{"key":"1135_CR75","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1016\/j.jash.2014.08.013","volume":"8","author":"GD Kitas","year":"2014","unstructured":"Kitas GD, Abreu G, Jedrychowicz-Rosiak K, Miller JL, Nakov R, Panfilov S, et al. The effects of the spleen tyrosine kinase inhibitor fostamatinib on ambulatory blood pressure in patients with active rheumatoid arthritis: results of the OSKIRA-ABPM (ambulatory blood pressure monitoring) randomized trial. J Am Soc Hypertens. 2014;8:780\u201390.","journal-title":"J Am Soc Hypertens"},{"key":"1135_CR76","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.632551","volume":"12","author":"Y Chen","year":"2021","unstructured":"Chen Y, Liu H, Huang Y, Lin S, Yin G, Xie Q. The cardiovascular risks of fostamatinib in patients with rheumatoid arthritis: a systematic review and meta-analysis. Front Pharmacol. 2021;12: 632551.","journal-title":"Front Pharmacol"},{"key":"1135_CR77","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1002\/bdra.20505","volume":"85","author":"GR Clemens","year":"2009","unstructured":"Clemens GR, Schroeder RE, Magness SH, Weaver EV, Lech JW, Taylor VC, et al. Developmental toxicity associated with receptor tyrosine kinase Ret inhibition in reproductive toxicity testing. Birth Defects Res A Clin Mol Teratol. 2009;85:130\u20136.","journal-title":"Birth Defects Res A Clin Mol Teratol"}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-022-01135-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40262-022-01135-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-022-01135-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,15]],"date-time":"2025-04-15T07:07:25Z","timestamp":1744700845000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40262-022-01135-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7]]},"references-count":77,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["1135"],"URL":"https:\/\/doi.org\/10.1007\/s40262-022-01135-0","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"value":"0312-5963","type":"print"},{"value":"1179-1926","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7]]},"assertion":[{"value":"2 May 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 July 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No funding was received for the preparation of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"The authors have no conflicts of interest that are directly relevant to the content of this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest\/Competing interests"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"Not applicable.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 contributions"}}]}}